

MATERIAL CHANGE REPORT

Item 1. Name and Address of Company

Beyond Medical Technologies Inc. (the "Company")
1111 West Hastings Street, 15th Floor
Vancouver, B.C. V6E 2J3

Item 2. Date of Material Change

The date of the material change is February 11, 2025.

Item 3. News Release

A news release with respect to the material change was disseminated through Newsfile Corp. on February 11, 2025.

Item 4. Summary of Material Change

Vancouver, British Columbia - Beyond Medical Technologies Inc. (CSE: DOCT) (FSE: 7FM) (OTC Pink: DOCKF) ("Beyond Medical" or the "Company") has announced plans for a non-brokered private placement of up to 7.5 million units at \$0.05 per unit, aiming to raise \$375,000 in gross proceeds. Each unit includes one common share and one warrant, allowing the holder to purchase an additional share at \$0.075 within 24 months.

The securities will be subject to a four-month statutory hold period, and finder's fees may apply under Canadian Securities Exchange policies. The company plans to use the proceeds to settle outstanding debt and cover general administrative expenses.

Item 5. Full Description of Material Change

Item 5.1 Full Description of Material Change

Vancouver, British Columbia - Beyond Medical Technologies Inc. (CSE: DOCT) (FSE: 7FM) (OTC Pink: DOCKF) ("Beyond Medical" or the "Company") intends to complete a non-brokered private placement of up to 7.5 million units at a price of five cents per unit for aggregate gross proceeds of up to \$375,000.

Each unit will consist of one common share in the capital of the company and one common share purchase warrant. Each warrant will entitle the holder thereof to purchase one share at a price of 7.5 cents per share for a period of 24 months from the date of issuance.

The securities offered pursuant to the offering will be subject to a statutory hold period of four months and a day from the date of issuance. Finders' fees may be payable in connection with the offering, all in accordance with the policies of the Canadian Securities Exchange.

The company intends to use the net proceeds of the offering to settle outstanding debt and for general and administrative expenses.

Item 5.2 Disclosure for Restructuring Transactions

Not applicable.

Item 6. Reliance on subsection 7.1(2) of National Instrument 51-102

Not applicable.

Item 7. Omitted Information

Not applicable.

Item 8. Executive Officer

Daniel Liu
Chief Executive Officer
Telephone: (650) 676-9562

Item 9. Date of Report

February 14, 2025